In the run up to our Advances in Immuno-Oncology USA Congress , we are delighted to invite you to participate in our free pre-congress webinar.

"The Role For TNFR2 In The Tumor Microenvironment"

 

Hosted by Russell LaMontagne, President and Chief Executive Officer

Boston Immune Technologies and Therapeutics.

Thursday 14th June | 5pm BST 9am PST
Can't make the date? Still register and the recording can be sent to you afterwards

Boston Immune Technologies and Therapeutics have made strides over the last few years in developing immune based approaches for the treatment of cancer and infectious diseases. From the oncology side, Russell and his team are developing a platform to target tumours with TNFR2 receptors, which target the immunosuppressive T Cells that protect tumours against checkpoint inhibitors.

Listen to his free live webinar and benefit from insights into:

 

 

Register for free today: https://bit.ly/2L0l2LD

 

Russell LaMontagne
Co-Founder, President and CEO

Russell has been senior advisor to biotechnology and pharmaceutical companies for over 20 years. He played a predominant role in the development of several early stage companies and has advised pharmaceutical companies regarding commercialization strategies. Russell is also co-founder of Endobiome, Inc.

Find out more: https://bit.ly/2s8Ef55

Russell will also be presenting at the Advances in Immuno-Oncology USA Congress on 11-12 October 2018 in San Diego, USA.

 

The Congress will cover 2 interactive streams:

And will be co-located with the 3rd Annual Biomarkers & Precision Medicine Congress

 

Visit the Website: https://bit.ly/2s4NunV